Uppsala, Sweden, November 12th, 2007
Beactica AB announced today that it has entered into a drug discovery collaboration agreement with Arrow Therapeutics Ltd (London, UK) whereby Beactica will direct its novel characterisation technology at selected Arrow compounds against a confidential target.
"We are very pleased to be working with Arrow” said Beactica’s CEO, Dr Per Källblad. "The company has a world-class reputation for conducting break through research in the antiviral field and we look forward to applying our technology on their targets.”
CEO of Arrow Therapeutics, Dr Ken Powell, said "Working with Beactica provides us with an opportunity to apply a new technology that has already shown strong potential.”
For further information, please contact Dr Per Källblad, CEO Beactica, +46 (0)18 56 08 80, or Dr Ken Powell, CEO Arrow Therapeutics, +44 (0)20 7015 1000.
Beactica AB is a specialist drug discovery company, utilising its proprietary methodologies to evaluate the biophysical interaction of molecules in order to generate novel therapeutics. As well as building collaborations with external companies, Beactica is progressing its own drug discovery programmes.
Arrow Therapeutics Ltd is a fully integrated pharmaceutical company, focused exclusively on the discovery and development of novel antiviral therapeutics in areas of significant unmet need. Established in 1998 and acquired by AstraZeneca in February 2007, Arrow specialises in small molecule drugs with novel mechanisms of action. The company has a number of research and development programs, the most advanced of which target Respiratory Syncytial Virus (RSV) and Hepatitis C Virus (HCV).
For more information about Arrow, please visit www.arrowt.co.uk
Sign up for the Beactica newsletter to receive our latest news and updates